Specsavers ECONOMIC

Target: Specsavers Research date: 23 October 2026 Reporting periods examined: 2023–2026, with selected historical records. Scope: Corporate group, supply chain, ownership, capital flows, Israeli economic activity and settlement-related commerce.

Supply Chain & Sourcing Relationships

Global supply-chain structure

Specsavers’ 2025–2026 annual review reports a global business with 2,987 optical, audiology, domiciliary and ophthalmology businesses, 46,792 colleagues, approximately 50 million customers and 653 million contact lenses sold during the reporting year.¹

The company’s supply-chain recruitment materials describe central responsibility for ophthalmic lenses, frames, contact lenses, manufacturing, purchasing and product distribution, supported by local store partners.²

The FY2024 corporate review identifies Szatmár Optikai in Hungary, Century Optic in Zhuhai, China, International Glazing Services in the UK and Melbourne Glazing Services in Australia as manufacturing or glazing operations.³

In 2024, Specsavers reported that its Chinese Century Optic joint-venture manufacturing facility had become fully operational in 2023 and was supplying approximately two million surfaced lenses annually to Australia and New Zealand.³

The same review reported that Szatmár Optikai glazed more than 3.3 million frames annually and had expanded lens-surfacing capacity to more than 800,000 lenses monthly.³

Named optical suppliers and private-label relationships

Vision Direct identifies CooperVision, Alcon, Bausch + Lomb and other manufacturers behind products corresponding to Specsavers’ easyvision contact-lens range.⁴

Vision Direct separately explains that Specsavers and other high-street optical retailers sell manufacturer-produced lenses under proprietary retail brands.⁵

Feel Good Contacts independently lists Specsavers easyvision products alongside equivalent lenses and named manufacturers, including CooperVision, Bausch + Lomb and Alcon.⁶

These manufacturer-equivalence disclosures do not establish the country of manufacture for individual products or shipments supplied to Specsavers.⁴

Direct Israeli sourcing

No public evidence identified establishing direct Specsavers procurement from Israeli optical manufacturers, agricultural exporters, wholesalers or manufacturing subcontractors in the reviewed FY2024–FY2026 corporate disclosures.^{1, 3}

No public evidence identified of a Specsavers commercial relationship with Mehadrin, Hadiklaim, Galilee Export or Agrexco successors in the reviewed supply-chain information.^{2, 3}

Importer-of-record structure

No public evidence identified of a Specsavers-controlled Israeli import subsidiary, dedicated Israel-origin importer, customs joint venture or other importer-of-record structure specifically handling Israeli-origin products.^{2, 3}

Seasonal sourcing

No public evidence identified of recurring December–April procurement from Israeli agricultural suppliers or comparable seasonal Israeli sourcing arrangements.^{2, 3}

Third-party and indirect sourcing

The documented use of manufacturers for easyvision contact lenses establishes that third-party manufacturing forms part of Specsavers’ supply arrangements.^{4, 5}

No public evidence identified that these arrangements caused Israeli-origin products to enter Specsavers’ supply chain through a named Israeli manufacturer, distributor or white-label supplier.^{4, 6}

Settlement-specific supply chain

No public evidence identified establishing procurement by Specsavers or its disclosed manufacturing operations from businesses located in Israeli settlements in the West Bank, including East Jerusalem, or the occupied Golan Heights.^{1, 3}

Product Origin, Labeling & Regulatory Compliance

Applicable UK rules

UK government guidance updated in June 2026 explains that products originating in Israeli settlements within territories occupied since 1967 must be distinguished from goods originating in Israel when applying relevant origin-labeling requirements.⁷

The corresponding UK guidance on business risks in the occupied Palestinian territories confirms the government’s position concerning settlement commerce, territorial origin and business-related human-rights risks.⁸

Customs treatment

The UK Notice to Importers updated on 22 August 2025 states that products produced in Israeli settlements within territories brought under Israeli administration since June 1967 are ineligible for preferential treatment under the UK-Israel Trade and Partnership Agreement.⁹

The government’s accompanying publication maintains a list of non-eligible settlement locations and postal codes for import-origin verification.¹⁰

UK Customs Declaration Service guidance records that document code Y864 was extended in 2025 in connection with Israeli-origin preference declarations.¹¹

Settlement-origin products

No public evidence identified establishing that Specsavers sold products manufactured in Israeli settlements or marketed settlement-produced goods under an Israeli country-of-origin designation.^{1, 3}

Labeling compliance and enforcement

No public evidence identified of a Specsavers-specific UK regulatory finding, customs penalty, misleading-origin enforcement action or official investigation concerning Israeli settlement-produced goods.^{9, 10}

The cited government notices establish general regulatory requirements and do not identify Specsavers as an investigated importer.⁹

Corporate labeling policy

No public evidence identified of an explicit Specsavers corporate policy addressing sourcing or labeling of products originating in Israeli settlements or other occupied territories within the reviewed corporate disclosures.^{1, 2}

Product traceability

The publicly documented identification of manufacturer-equivalent contact lenses does not establish factory-level origins or batch-level traceability for the full easyvision product range.^{4, 6}

Investment, Capital & Financial Exposure

Corporate capital position

The Specsavers FY2026 annual review reports group revenue of £4.54 billion for the financial year ending February 2026, representing 8.9% growth on the previous year.¹

An independent analysis of UK statutory accounts reports turnover of approximately £4.262 billion and profit before tax of approximately £430 million for Specsavers Optical Superstores Limited for the year ending February 2026.¹²

A separate financial-data publication reports approximately 46,616 employees and £506 million in net assets for the UK reporting group for the same accounting period.¹³

Foreign direct investment in Israel

No public evidence identified of Specsavers acquiring Israeli factories, offices, warehouses, data centres, retail properties or other controlling operational assets in Israel or occupied territories.^{1, 14}

Disclosed historical acquisitions

Specsavers’ corporate history records the acquisition of Swedish optical group Blic in 2004 [pre-2020], Danish optical business Louis Nielsen in 2005 [pre-2020] and UK domiciliary eyecare business Healthcall in 2013 [pre-2020].¹⁴

The company also records its partnership with UK ophthalmology provider Newmedica beginning in 2016 [pre-2020] and its entry into the US market through a partnership with contact-lens e-commerce business Waldo in 2024.¹⁴

These disclosed acquisition and partnership records do not identify an Israeli operating company acquired by Specsavers.¹⁴

Acquired Israeli subsidiaries

No public evidence identified of an Israeli operating company acquired by Specsavers or held under a disclosed controlling ownership stake as of October 2026.^{1, 14}

Accordingly, no verified Israeli subsidiary acquisition date, transaction consideration, current ownership percentage, Israeli factory address, Israeli employee count, revenue contribution, market position or defence-related commercial relationship could be established.^{1, 14}

Distinguishing unrelated investments

In 2022, Fielmann Ventures announced an agreement to acquire a 10% equity stake in Israeli optical-technology company Deep Optics, based in Petah Tikva.¹⁵

The announcement identifies Fielmann Ventures as the investor and provides no evidence that the investment was made by Specsavers or a Specsavers-controlled entity.¹⁵

R&D and innovation

In January 2026, professional optical-industry reporting identified Specsavers directors Giles Edmonds and Paul Morris as participants in an artificial-intelligence discussion alongside representatives associated with Cascader, Moorfields Eye Hospital, UCL Institute of Ophthalmology and Topcon Healthcare.¹⁶

No public evidence identified of a Specsavers-operated Israeli research centre, Israeli innovation accelerator, Israeli technology-development subsidiary or Israeli government-funded R&D programme.^{1, 16}

Parent ownership and financial control

Reporting published in January 2023 states that Specsavers’ business had been placed within a family trust designed to preserve long-term ownership.¹⁷

A separate professional optical-industry report confirms that Specsavers was placed into a family trust in 2023, identifies John Perkins as CEO and describes the group’s joint-venture partnership model.¹⁸

Portfolio exposure

No public evidence identified of direct holdings by Specsavers or its disclosed corporate parent in Israeli-domiciled companies, Israeli sovereign bonds or Israel-focused investment funds.^{1, 12}

Controlling-principal investments

No public evidence identified establishing material Israeli corporate investments by Doug Perkins, Mary Perkins, John Perkins or their disclosed family-trust arrangements.^{17, 18}

Financing the Israeli state

No public evidence identified of Specsavers underwriting Israeli sovereign debt, arranging war bonds, distributing Israel Bonds, financing Israeli defence companies or lending directly to settlement-associated companies.^{1, 12}

Financial-sector applicability

Specsavers’ disclosed operations centre on optometry, audiology, ophthalmology, manufacturing and associated healthcare retail, with no disclosed investment-banking or insurance-underwriting business.^{1, 19}

Operational Presence & Market Activity

Geographic retail operations

Specsavers’ FY2026 annual review identifies operating businesses in the United Kingdom, Ireland, Netherlands, Norway, Sweden, Denmark, Finland, Australia, New Zealand and Canada.¹

The review reports approximately 941 optical businesses in the UK, 396 in Australia, 271 in Canada, 143 in the Netherlands, 121 in Sweden, 84 in Norway and 80 in Denmark at February 2026.¹

The published country breakdown contains no Israeli retail-market entry or Israeli operating-business count.¹

Support offices

Specsavers advertises central support-office roles in Guernsey and the United Kingdom, including finance, supply chain, retail operations and corporate support.²⁰

The group’s Northern European recruitment pages describe operational activity and professional recruitment across its regional markets.²¹

Physical footprint in Israel

No public evidence identified of Specsavers-operated Israeli stores, authorised Israeli optical franchise locations, offices, warehouses, laboratories or manufacturing facilities.^{1, 21}

Employment and taxation in Israel

No public evidence identified of an Israeli payroll, Israeli tax registration, Israeli corporate tax-residency status or Preferred Technology Enterprise designation attributable to Specsavers.^{1, 12}

Market positioning

No public evidence identified of Specsavers characterising Israel as an export destination, strategic growth market, research hub or established operating region in its FY2024–FY2026 annual reviews.^{1, 3}

Military and government contracts

The January 2026 professional-industry coverage identifies UK healthcare-sector engagement with Specsavers executives and NHS-related technology discussions.¹⁶

No public evidence identified of Specsavers contracts with the Israel Defense Forces, Israeli Ministry of Defence, Israeli defence manufacturers or Israeli government procurement authorities.^{1, 16}

Settlement-market operations

No public evidence identified establishing Specsavers sales outlets, licensee operations, franchised stores, distribution facilities or identified revenue-generating services within Israeli settlements.^{1, 21}

Activity after July and November 2024

Specsavers’ FY2026 annual review confirms substantial continuing international commercial operations through February 2026.¹

No public evidence identified establishing that an Israeli or settlement-specific commercial relationship continued after 19 July 2024 or after November 2024.^{1, 3}

DVLA vision-testing services contract (2024–2028): UK public-procurement records identify Specsavers Optical Superstores Limited as the successful supplier for Driver and Vehicle Licensing Agency (DVLA) contract PS/21/126, Provision of Vision Testing Services. The contract award was published on 11 December 2024, with an award or contract-conclusion date of 9 December 2024 recorded by procurement-data aggregators. The published award value was £12,340,000. This establishes a substantial UK central-government commercial relationship, although the published contract value does not establish the amount ultimately paid to Specsavers.^{22, 23, 24}

Contract duration and scope: The agreement commenced on 1 April 2025, with an initial three-year term ending on 31 March 2028 and options for two additional 12-month extensions. Its scope covers visual-field and visual-acuity examinations conducted by qualified optometrists or opticians to assist the DVLA in assessing drivers’ medical fitness to hold driving licences. The supplier must provide Group 1 and Group 2 visual-field standard tests, nationwide coverage throughout Great Britain, and a central management hub serving DVLA stakeholders and customers. The procurement was conducted through an open procedure.^{23, 24, 25}

Parliamentary confirmation and award-date discrepancy: In a written parliamentary answer dated 11 February 2026, Transport Minister Simon Lightwood confirmed that Specsavers held the DVLA eyesight-testing contract, that services commenced on 1 April 2025, and that the initial three-year term included options for two further one-year extensions. However, the minister described the contract as awarded in February 2025, whereas the published procurement records identify December 2024 as the award or contract-conclusion period. A separate parliamentary answer dated 5 January 2026 also gives February 2025. The available records therefore establish the contract’s existence and commencement but contain an unresolved discrepancy concerning the precise award date.^{23, 25, 26}

Published-value interpretation: The Contracts Finder-derived record reports £12,340,000, while a separate Find a Tender-derived procurement record for the same reference, PS/21/126, reports a contract value of £15,600,000. These records should not be treated as evidence of two separate contracts or added together. The £12.34 million figure is independently reproduced by multiple procurement aggregators, but the available secondary records do not conclusively reconcile the differing published values or establish final expenditure, annual payments, extension utilisation or realised supplier revenue.^{22, 23, 24, 27}

Service-provider arrangements: In its parliamentary response of 11 February 2026, the Department for Transport confirmed that the DVLA may consider eyesight examinations performed by an optometrist or ophthalmologist other than Specsavers. Such examinations must meet DVLA specifications and are undertaken at the individual’s own expense. Applicants may subsequently be required to undergo another examination through Specsavers if the alternative examination fails to meet those specifications. The contract therefore establishes Specsavers as the DVLA’s contracted testing provider without establishing an absolute prohibition on independently obtained examinations.²⁵

DVLA contract award date - procurement-record reconciliation: The published procurement data for DVLA contract PS/21/126 establishes 9 December 2024 as the recorded contract award or signing date. The Contracts Finder-derived Open Contracting Data Standard (OCDS) record explicitly identifies awards[0].date as 2024-12-09 and awards[0].datePublished as 11 December 2024. The separate Find a Tender-derived record identifies contracts[0].dateSigned as 9 December 2024, with its contract award notice published on 10 December 2024. An amendment followed on 11 December 2024. These dates distinguish the recorded award/signing event from subsequent publication. This confirms the existing audit statement identifying December 2024 as the procurement-record award period and establishes 9 December 2024 more precisely. It also confirms that 11 December 2024 was a publication date, rather than the recorded contract-signing date.^{28, 23}

February 2025 parliamentary discrepancy: The Department for Transport’s parliamentary answer of 11 February 2026 expressly describes the Specsavers contract as awarded in February 2025, despite the December 2024 award and signing dates recorded in the procurement notices. The parliamentary answer confirms commencement on 1 April 2025 but provides no explanation for the different award month. The available evidence therefore supports December 2024 as the recorded procurement award/signing date while leaving the minister’s February 2025 description unexplained. This refines the existing audit’s “Parliamentary confirmation and award-date discrepancy” statement: the discrepancy is demonstrable, but no verified administrative explanation establishes whether February 2025 refers to a subsequent approval, contractual milestone or ministerial reporting error.^{28, 23, 29}

DVLA contract value - original notice and subsequent amendment: The Find a Tender-derived procurement record contains an explicit amendment correcting both section II.1.7, “Total value of the procurement (excluding VAT)”, and section V.2.4, “Information on value of contract/lot (excluding VAT)”. Both sections originally stated £15,600,000 and were amended to £12,340,000. The amendment was published on 11 December 2024, following the 10 December 2024 contract award notice. The £15.6 million figure therefore represents the originally published contract/procurement value, excluding VAT, while £12.34 million represents the subsequently corrected value, also excluding VAT. The difference is £3,260,000, approximately 20.9% of the original figure. This resolves the existing audit’s “Published-value interpretation” discrepancy: the two figures are successive published values for the same procurement, with an explicit correction documented in the official notice history reproduced in the OCDS record.^{28, 23}

Corrected award value and financial interpretation: The Contracts Finder-derived award record separately identifies £12,340,000 as both the tender value and the awarded value, while the Find a Tender correction expressly replaces £15,600,000 with £12,340,000 in the procurement-total and contract/lot-value fields. Accordingly, £12,340,000 is the corrected published award value for PS/21/126, and £15,600,000 is the superseded amount. The recorded figures are excluding VAT. Neither record establishes actual payments, realised Specsavers revenue, expenditure attributable specifically to the initial three-year term, or utilisation of the optional extensions. This confirms the existing audit’s caution against treating published contract values as actual expenditure, while correcting its statement that the two values could not conclusively be reconciled.^{28, 23}

Corporate Structure & Foundational Ties

Founding

Specsavers’ corporate history identifies the business as established by optometrists Doug and Mary Perkins in Guernsey in 1984.³⁰

Its Northern European corporate recruitment materials likewise identify Guernsey as the founding location and 1984 as the foundation year.³¹

UK incorporation

Companies House filing history identifies Specsavers Optical Superstores Limited as an established UK legal entity with historical statutory accounts and corporate filings.³²

The UK company was incorporated on 9 May 1983, originally under the name Changecrest Limited, before subsequently trading under optical-business names.¹²

Headquarters and domicile

The disclosed group operates through Guernsey-based leadership and corporate support alongside registered UK subsidiaries and multiple international regional operations.^{1, 20}

No public evidence identified of an Israeli headquarters, legacy Israeli domicile, dual Israeli headquarters or Israeli principal place of management.^{1, 31}

Current principal officers

Companies House identifies Douglas John David Perkins, Mary Lesley Perkins and John Douglas Perkins among active directors of Specsavers Optical Superstores Limited.³³

The same corporate register identifies Thomas Michael Buller, Paul Bryan Fussey and Peter Dominic John Wright among other active directors.³³

The FY2026 annual review identifies Doug Perkins as chairman and founder and Dame Mary Perkins as founder.¹

Family governance

Reporting in January 2023 described the transfer of the business into a family trust intended to preserve long-term family ownership and prevent an eventual private-equity sale.¹⁷

Further reporting identified the family trust as supporting continued Perkins-family stewardship alongside Specsavers’ established joint-venture business model.¹⁸

A January 2026 industry report confirmed that Doug Perkins continued as chairman and John Perkins as CEO, while describing the company’s long-standing family ownership.³⁴

Joint-venture governance

Specsavers’ published partnership model provides for local optical and audiology store partners to hold ownership interests and manage individual businesses, with the wider group supplying operational and commercial support.¹⁹

Israeli-Nexus Floor factors

Founded in Israel: The documented founding location is Guernsey, with the Specsavers business established in 1984.³⁰

Israeli headquarters: The disclosed headquarters and corporate leadership structure is centred on Guernsey and the group’s other reported operating jurisdictions.^{1, 20}

Israeli tax residency or PTE status: no public evidence identified in the reviewed corporate and statutory reporting.^{1, 12}

Beneficial ownership by Israeli capital: The available ownership disclosures identify Perkins-family and family-trust control, with no verified Israeli controlling shareholder.^{17, 18}

Israeli state ownership or appointments

No public evidence identified of Israeli state equity ownership, Israeli government-appointed board members, government golden shares or state-directed governance rights within Specsavers.^{17, 33}

Structural governance ties

No public evidence identified of governance restrictions, reserved shares, constitutional provisions or control rights linking Specsavers’ corporate purpose or operations to Israeli state policy.^{17, 33}

Controlling principals and related interests

No public evidence identified establishing Israeli defence-industry directorships, settlement-business ownership or material Israeli operating investments attributable to the identified controlling Perkins family members.^{17, 33}

Profit Repatriation & Economic Contribution

Global revenue

Specsavers reported £4.54 billion in group revenue for FY2026, with reported regional growth of 9.4% in UK/Ireland, 5.1% in Northern Europe, 7.1% in Australia/New Zealand and 34.9% in North America.¹

The same annual review reported approximately 50 million customers globally and 26 million frames sold during the reporting year.¹

Israel-attributed revenue

No public evidence identified of Israel-specific group revenue, sales, operating profit, royalty income or market-share disclosures in the reviewed FY2024–FY2026 annual reviews.^{1, 3}

Financial results and distributions

The FY2026 UK reporting group’s approximately £4.262 billion turnover and £430 million pre-tax profit are reported by independent analyses of Companies House accounts.^{12, 13}

The UK statutory filing history identifies the group’s accounts made up to 28 February 2026 as filed on 19 August 2026.³²

Israeli profit repatriation

No public evidence identified of dividends, management fees, royalties, intercompany financing or other repatriated profits flowing from Specsavers’ international businesses to Israeli-domiciled owners.^{1, 17}

No public evidence identified of profits generated by Israeli Specsavers subsidiaries and subsequently remitted to Guernsey or other overseas group entities.^{1, 12}

Tax contribution

No public evidence identified of Israeli corporation-tax payments, Israeli employer-tax contributions, VAT remittances or other identifiable Israeli fiscal contributions by Specsavers.^{1, 12}

Contribution through suppliers

The disclosed manufacturing network includes facilities in Hungary, China, Australia and the UK, with significant manufacturing output attributable to those locations.³

No public evidence identified quantifying procurement expenditure paid by Specsavers to Israeli manufacturers, distributors or component suppliers.^{2, 3}

Role within the Israeli economy

No public evidence identified of an Israeli government designation, sectoral ranking or industry assessment identifying Specsavers as an important Israeli optical-sector employer, manufacturer, investor or infrastructure provider.^{1, 21}

Controlling-family economic contribution

Available public reporting identifies a Guernsey-based family business with established family-trust arrangements.^{17, 18}

No public evidence identified establishing an attributable material Israeli investment or identifiable Israeli economic contribution by the Perkins family through Specsavers ownership or separately disclosed family investment vehicles.^{17, 34}